MCID: LCL004
MIFTS: 34

Localized Osteosarcoma

Categories: Bone diseases, Cancer diseases

Aliases & Classifications for Localized Osteosarcoma

MalaCards integrated aliases for Localized Osteosarcoma:

Name: Localized Osteosarcoma 12 15 70
Localised Osteogenic Sarcoma 12
Localized Osteogenic Sarcoma 12
Localised Osteosarcoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3356
NCIt 50 C7780
UMLS 70 C0278511

Summaries for Localized Osteosarcoma

MalaCards based summary : Localized Osteosarcoma, also known as localised osteogenic sarcoma, is related to osteogenic sarcoma and parotid gland adenoid cystic carcinoma. An important gene associated with Localized Osteosarcoma is CSF3 (Colony Stimulating Factor 3), and among its related pathways/superpathways are Gastric cancer and Glioma. The drugs Ifosfamide and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include bone, liver and lung.

Related Diseases for Localized Osteosarcoma

Diseases related to Localized Osteosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 166)
# Related Disease Score Top Affiliating Genes
1 osteogenic sarcoma 30.5 TP53 IGF1R FRZB CDKN2A
2 parotid gland adenoid cystic carcinoma 10.3 ERBB2 CDKN2A
3 vulva basal cell carcinoma 10.3 ERBB2 CDKN2A
4 vulvar intraepithelial neoplasia 10.3 TP53 CDKN2A
5 esophagus verrucous carcinoma 10.3 TP53 CDKN2A
6 ovarian seromucinous carcinoma 10.3 TP53 CDKN2A
7 human papillomavirus infectious disease 10.3 TP53 CDKN2A
8 spitz nevus 10.2 TP53 CDKN2A
9 breast papillomatosis 10.2 ERBB2 CDKN2A
10 soft tissue sarcoma 10.2 TP53 CSF3
11 squamous cell papilloma 10.2 TP53 CDKN2A
12 fallopian tube endometrioid adenocarcinoma 10.2 ERBB2 CDKN2A
13 penile benign neoplasm 10.2 TP53 CDKN2A
14 bizarre leiomyoma 10.2 TP53 CDKN2A
15 adult malignant schwannoma 10.2 TP53 CDKN2A
16 supraglottis cancer 10.2 TP53 CDKN2A
17 suppressor of tumorigenicity 3 10.2 TP53 CDKN2A
18 malignant exocrine pancreas neoplasm 10.2 TP53 CDKN2A
19 chronic cervicitis 10.2 TP53 CDKN2A
20 thyroid lymphoma 10.2 TP53 CDKN2A
21 bladder clear cell adenocarcinoma 10.2 TP53 CDKN2A
22 middle ear carcinoma 10.2 EWSR1 CSF3 CDKN2A
23 keratinizing squamous cell carcinoma 10.2 TP53 CDKN2A
24 male reproductive organ benign neoplasm 10.2 TP53 CDKN2A
25 malignant spiradenoma 10.2 TP53 CDKN2A
26 bile duct adenoma 10.2 TP53 CDKN2A
27 vulva squamous cell carcinoma 10.2 TP53 CDKN2A
28 vaginal cancer 10.2 TP53 CDKN2A
29 nasal cavity adenocarcinoma 10.2 TP53 CDKN2A
30 bone squamous cell carcinoma 10.2 TP53 CDKN2A
31 low-grade astrocytoma 10.2 TP53 CDKN2A
32 gliofibroma 10.2 TP53 CDKN2A
33 nasal cavity cancer 10.2 TP53 CDKN2A
34 gastric papillary adenocarcinoma 10.2 TP53 ERBB2
35 childhood malignant schwannoma 10.2 TP53 EWSR1
36 prostate squamous cell carcinoma 10.2 TP53 CDKN2A
37 borst-jadassohn intraepidermal carcinoma 10.2 TP53 CDKN2A
38 familial retinoblastoma 10.2 TP53 CDKN2A
39 apocrine adenosis of breast 10.2 TP53 ERBB2
40 neurofibrosarcoma 10.2 TP53 CDKN2A
41 laryngeal benign neoplasm 10.2 TP53 CDKN2A
42 parotid gland cancer 10.2 TP53 ERBB2
43 comedo carcinoma 10.2 TP53 ERBB2
44 acanthoma 10.2 TP53 CDKN2A
45 vulvar dystrophy 10.2 TP53 CDKN2A
46 megaesophagus 10.2 TP53 CDKN2A
47 breast sarcoma 10.2 TP53 ERBB2
48 breast malignant phyllodes tumor 10.2 TP53 ERBB2
49 pleomorphic adenoma carcinoma 10.2 TP53 ERBB2
50 esophageal adenosquamous carcinoma 10.2 TP53 ERBB2

Graphical network of the top 20 diseases related to Localized Osteosarcoma:



Diseases related to Localized Osteosarcoma

Symptoms & Phenotypes for Localized Osteosarcoma

Drugs & Therapeutics for Localized Osteosarcoma

Drugs for Localized Osteosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ifosfamide Approved Phase 3 3778-73-2 3690
2
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
3
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
4
Peginterferon alfa-2b Approved Phase 3 99210-65-8, 215647-85-1
5
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
6
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
7
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
8
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
9
Lenograstim Approved, Investigational Phase 3 135968-09-1
10
Dexrazoxane Approved, Withdrawn Phase 3 24584-09-6 71384
11
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
13
Etoposide Approved Phase 3 33419-42-0 36462
14
Zoledronic Acid Approved Phase 3 118072-93-8 68740
15
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
16
Cyproheptadine Approved Phase 3 129-03-3 2913
17
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
18 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
19 Alkylating Agents Phase 3
20 Immunosuppressive Agents Phase 3
21 Antirheumatic Agents Phase 3
22 Immunologic Factors Phase 3
23
Isophosphamide mustard Phase 3 100427
24 Antiviral Agents Phase 3
25 interferons Phase 3
26 Interferon-alpha Phase 3
27 Interferon alpha-2 Phase 3
28 Tubulin Modulators Phase 3
29 Keratolytic Agents Phase 3
30 Podophyllotoxin Phase 3 518-28-5
31 Liver Extracts Phase 3
32 Vitamin B9 Phase 3
33 Antibiotics, Antitubercular Phase 3
34
Liposomal doxorubicin Phase 3 31703
35 Folic Acid Antagonists Phase 3
36 Vitamin B Complex Phase 3
37 Folate Phase 3
38 Antimetabolites Phase 3
39 Anti-Bacterial Agents Phase 3
40 Anti-Infective Agents Phase 3
41 Analgesics Phase 3
42 Cola Phase 3
43 razoxane Phase 3
44 Cardiotonic Agents Phase 3
45 Antimitotic Agents Phase 3
46 Antidotes Phase 3
47 Protective Agents Phase 3
48 Chelating Agents Phase 3
49 sodium thiosulfate Phase 3
50 Antioxidants Phase 3

Interventional clinical trials:

(show all 29)
# Name Status NCT ID Phase Drugs
1 A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-operative Chemotherapy Unknown status NCT00134030 Phase 3 Cisplatin;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Methotrexate
2 A RANDOMISED TRIAL OF CHEMOTHERAPY WITH OR WITHOUT GRANULOCYTE COLONY-STIMULATING FACTOR IN OPERABLE OSTEOSARCOMA Completed NCT00002539 Phase 3 cisplatin;doxorubicin hydrochloride
3 Protocol for Patients With Newly-Diagnosed Non-Metastatic Osteosarcoma - A POG/CCG Pilot Intergroup Study Completed NCT00003937 Phase 3 cisplatin;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;methotrexate
4 A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children Completed NCT00716976 Phase 3 sodium thiosulfate
5 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
6 OS2006 : Protocole de Traitement Des ostéosarcomes de l'Enfant, de l'Adolescent et de l'Adulte Comportant Active, not recruiting NCT00470223 Phase 3 cisplatin;doxorubicin hydrochloride;etoposide;ifosfamide;methotrexate;zoledronic acid
7 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
8 Phase II Study of Low-Dose Interferon Alfa 2B (Schering Plough) Plus Thalidomide (Celgene) for Patients With Resected High-Risk Soft Tissue Sarcoma Unknown status NCT00026416 Phase 2 thalidomide
9 High Dose Samarium-153 With Peripheral Blood Stem Cell Support in High Risk Osteogenic Sarcoma Completed NCT00245011 Phase 2 ifosfamide
10 Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, and Ifosfamide, Followed by Resection and Radiotherapy in Patients With Peripheral Primitive Neuroectodermal Tumors or Ewing's Sarcoma Completed NCT00002466 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
11 Osteosarcoma: Outcome of Therapy Based on Histologic Response. A Collaborative Effort of the POB/NCI, Texas Children's Hospital and University of Oklahoma. Terminated NCT00019864 Phase 2 cisplatin;dexrazoxane hydrochloride;doxorubicin hydrochloride;leucovorin calcium;methotrexate
12 A Phase II Study of Sorafenib and Ifosfamide as a Treatment for Patients With Sarcoma Terminated NCT00880542 Phase 2 sorafenib;Ifosfamide
13 A Pilot Study of Irradiated HLA-Partially Matched Allogeneic Related Donor Lymphocytes for Patients With Selected Malignancies Completed NCT00161187 Phase 1
14 PHASE I PILOT STUDY OF SEQUENTIAL HIGH DOSE CYCLES OF CISPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE AND IFOSFAMIDE, CARBOPLATIN AND TAXOL WITH AUTOLOGOUS STEM CELL SUPPORT Completed NCT00002854 Phase 1 carboplatin;cisplatin;cyclophosphamide;etoposide;ifosfamide;mesna;paclitaxel
15 Therapeutically Applicable Research to Generate Effective Treatments (TARGET) for Osteosarcoma Unknown status NCT01190943
16 Tumor Microenvironment in Patients With Localized Osteosarcoma Treated With Mifamurtide: a Translational Study Unknown status NCT03737435
17 Glucose Metabolic Response by PET/CT to Sarcoma Treatments Completed NCT00335751
18 Barriers to Patient Enrollment Onto Frontline Therapeutic Clinical Trials and Development of Intervention Strategies to Increase the Proportion of Enrollment Completed NCT00002485
19 Clinical and Biological Predictors of Therapy-Related Leukemia Completed NCT00003793
20 A Randomized Study Of Electroacupuncture Treatment For Delayed Chemotherapy-Induced Nausea And Vomiting In Patients With Pediatric Solid Tumors Completed NCT00040911
21 Genomic Study of Metastatic Osteosarcoma Using Next-Generation Sequencing Technology Completed NCT01062438
22 Treatment of Newly Diagnosed Untreated Osteosarcoma: A Pilot Study of a New Chemotherapeutic Regimen Including Ifosfamide Completed NCT00645632 cisplatin;doxorubicin hydrochloride;ifosfamide;methotrexate
23 Observational - Tissue Factor Expression in Bone Sarcomas Completed NCT01807052
24 Observational - Methylation Status as Predictor of Response to Neoadjuvant Chemotherapy in Osteosarcoma Completed NCT01374672
25 Retrospective Study of Genetic Risk Factors for Osteosarcoma Completed NCT00954473
26 Localized Osteosarcoma of Extremities: Developing a Clinical Prediction Model From a Country With Limited Resources Completed NCT03839095
27 Sequential Administration of Cryoablation and Cyclophosphamide for Advanced Solid Epithelial Cancer Terminated NCT00499733 Early Phase 1 cyclophosphamide
28 Prevention of Mucositis in Children With AES-14 (IND#36978), a Glutamine Based Oral Care Regimen, for Patients Diagnosed With Solid Tumors: A Randomized Placebo-Controlled Clinical Study Withdrawn NCT00334984 glutamine
29 Prospective, Randomized Trial Comparing Heparin and Minocycline-EDTA Flush for the Prevention of Catheter-Related Infections and Occlusions Withdrawn NCT00378781 Heparin;Minocycline-EDTA

Search NIH Clinical Center for Localized Osteosarcoma

Genetic Tests for Localized Osteosarcoma

Anatomical Context for Localized Osteosarcoma

MalaCards organs/tissues related to Localized Osteosarcoma:

40
Bone, Liver, Lung, T Cells

Publications for Localized Osteosarcoma

Articles related to Localized Osteosarcoma:

(show top 50) (show all 118)
# Title Authors PMID Year
1
Clinical significance of indeterminate pulmonary nodules on the survival of 364 patients with nonmetastatic, high-grade, localized osteosarcoma: A 12-year retrospective cohort study. 61
33289124 2021
2
The prognostic significance of lymphovascular tumor invasion in localized high-grade osteosarcoma: Outcomes of a single institution over 10 years. 61
33621357 2021
3
The Plasma Concentration of D-Dimer is Associated with Neoadjuvant-Chemotherapy Efficacy and the Prognosis in Osteosarcoma. 61
33469302 2021
4
Radiological Assessment and Outcome of Local Disease Progression after Neoadjuvant Chemotherapy in Children and Adolescents with Localized Osteosarcoma. 61
33348627 2020
5
Prognostic factors in High-Grade Localized Osteosarcoma of the Extremities: The Tunisian Experience. 61
33283661 2020
6
Maintenance therapy and drug holiday in sarcoma patients: systematic review. 61
32400254 2020
7
Is Microscopic Vascular Invasion in Tumor Specimens Associated with Worse Prognosis in Patients with High-grade Localized Osteosarcoma? 61
31904683 2020
8
CORR® Tumor Board: Is Microscopic Vascular Invasion in Tumor Specimens Associated with Worse Prognosis in Patients with High-grade Localized Osteosarcoma? 61
32118597 2020
9
CORR Insights®: Is Microscopic Vascular Invasion in Tumor Specimens Associated with Worse Prognosis in Patients with High-grade Localized Osteosarcoma? 61
31977429 2020
10
Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma. 61
32475245 2020
11
Engineering 2D Mesoporous Silica@MXene-Integrated 3D-Printing Scaffolds for Combinatory Osteosarcoma Therapy and NO-Augmented Bone Regeneration. 61
32108432 2020
12
Age and Tumor Location Predict Survival in Nonmetastatic Osteosarcoma in Upper Egypt. 61
31107367 2020
13
Therapeutic Potential of Circular RNAs in Osteosarcoma. 61
32351876 2020
14
Prognostic Factors for Development of Subsequent Metastases in Localized Osteosarcoma: A Systematic Review and Identification of Literature Gaps. 61
32300279 2020
15
Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective. 61
32483726 2020
16
Pediatric Osteosarcoma of Extremities: A 15-year Experience From a Tertiary Care Cancer Center in Upper Egypt. 61
30629005 2019
17
Can pretreatment 18F-FDG PET tumor texture features predict the outcomes of osteosarcoma treated by neoadjuvant chemotherapy? 61
30859285 2019
18
Prognostic and clinicopathological significance of circulating tumor cells in osteosarcoma. 61
31024791 2019
19
Malignant Bone Tumors of the Knee: How to Identify and Treat. 61
30449025 2019
20
MiR-204-5p promotes apoptosis and inhibits migration of osteosarcoma via targeting EBF2. 61
30529043 2019
21
Lymphocyte-monocyte ratio at day 14 of first cisplatin-doxorubicin chemotherapy is associated with treatment outcome of pediatric patients with localized osteosarcoma. 61
30304898 2019
22
Crosstalk between Hh and Wnt signaling promotes osteosarcoma progression. 61
31933884 2019
23
Treatment-Related Prognostic Factors in Managing Osteosarcoma around the Knee with Limb Salvage Surgery: A Lesson from a Long-Term Follow-Up Study. 61
31187043 2019
24
The effect of PLGA-based hydrogel scaffold for improving the drug maximum-tolerated dose for in situ osteosarcoma treatment. 61
30193198 2018
25
Health-Related Quality of Life and Survival Outcomes of Pediatric Patients With Nonmetastatic Osteosarcoma Treated in Countries With Different Resources. 61
30241221 2018
26
Analysis of HSP27 and the Autophagy Marker LC3B+ Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients. 61
29592877 2018
27
Current and future therapeutic approaches for osteosarcoma. 61
29210294 2018
28
Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. 61
29340095 2017
29
A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy. 61
28631382 2017
30
Ewing Sarcoma of the Bone With EWS/FLI1 Translocation After Successful Treatment of Primary Osteosarcoma. 61
27918348 2017
31
p16 expression as a prognostic and predictive marker in high-grade localized osteosarcoma of the extremities: an analysis of 357 cases. 61
27544803 2016
32
Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis. 61
27457945 2016
33
Risk-Based Therapy for Localized Osteosarcoma. 61
26501936 2016
34
Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients. 61
26381138 2015
35
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. 61
26304877 2015
36
Prognostic value of pathologic fracture in patients with high grade localized osteosarcoma: a systemic review and meta-analysis of cohort studies. 61
25231396 2015
37
IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas. 61
26173023 2015
38
Letter to the editor: Surgical resection of relapse may improve postrelapse survival of patients with localized osteosarcoma. 61
25106799 2014
39
Reply to the Letter to the editor: Surgical resection of relapse may improve postrelapse survival of patients with localized osteosarcoma. 61
25099264 2014
40
Characterization of localized osteosarcoma of the extremity in children, adolescents, and young adults from a single institution in South Texas. 61
24487915 2014
41
Is it important to maintain high-dose intensity chemotherapy in the treatment of adults with osteosarcoma? 61
24719037 2014
42
Analysis of serum insulin growth factor-1 concentrations in localized osteosarcoma: a children's oncology group study. 61
24178953 2014
43
Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma. 61
24924182 2014
44
Conditional survival is greater than overall survival at diagnosis in patients with osteosarcoma and Ewing's sarcoma. 61
23821136 2013
45
Pathologic fracture does not influence prognosis in stage IIB osteosarcoma: a case-control study. 61
23799947 2013
46
Current therapeutic strategies and novel approaches in osteosarcoma. 61
24216993 2013
47
Surgical resection of relapse may improve postrelapse survival of patients with localized osteosarcoma. 61
22972657 2013
48
Targeting hedgehog-GLI-2 pathway in osteosarcoma. 61
22968906 2013
49
New targets and approaches in osteosarcoma. 61
22983152 2013
50
Pathologic fracture does not influence local recurrence and survival in high-grade extremity osteosarcoma with adequate surgical margins. 61
22740310 2012

Variations for Localized Osteosarcoma

Expression for Localized Osteosarcoma

Search GEO for disease gene expression data for Localized Osteosarcoma.

Pathways for Localized Osteosarcoma

GO Terms for Localized Osteosarcoma

Biological processes related to Localized Osteosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell growth GO:0030308 9.33 TP53 FRZB CDKN2A
2 replicative senescence GO:0090399 8.96 TP53 CDKN2A
3 negative regulation of immature T cell proliferation in thymus GO:0033088 8.62 ERBB2 CDKN2A

Molecular functions related to Localized Osteosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MDM2/MDM4 family protein binding GO:0097371 8.62 TP53 CDKN2A

Sources for Localized Osteosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....